In a move that could reshape the future of medical decision-making, OpenEvidence has secured a staggering $210 million in Series B funding, sending shockwaves through both the health tech sector and investment circles. Now valued at $3.5 billion, the Cambridge-based company’s mission is clear: bring real-time, evidence-based insights to the fingertips of clinicians using artificial intelligence built for the unique demands of modern healthcare.
AI at the Heart of the Hospital
The adoption curve for OpenEvidence has been nothing less than remarkable. Already active in over 10,000 hospitals and reaching 40% of US physicians, the platform is embedded into the daily rhythm of healthcare. Its secret sauce? Combining AI-powered search with partnerships spanning the American Medical Association, JAMA, and The New England Journal of Medicine—bringing trustworthy, peer-reviewed research right to the bedside.
These integrations allow OpenEvidence to sidestep the traditional scavenger hunt through fragmented databases. Instead, clinicians ask complex patient-specific questions and, within seconds, receive tailored, referenced responses—speeding up care, reducing cognitive overload, and sharply cutting research time from hours to moments.
DeepConsult™: Your AI Research Team
The latest announcement turns up the dial: OpenEvidence DeepConsult™, a team of autonomous, PhD-level, medically-specialized AI agents designed for the research needs of busy physicians. Imagine asking a time-consuming question before seeing your next patient, then returning from a break to find a comprehensive research synthesis ready in your inbox. DeepConsult efficiently cross-references hundreds of studies, surfacing critical insights and even uncovering interdisciplinary connections that might otherwise go unnoticed.
For US doctors, DeepConsult™ is free, making advanced medical research as accessible as a tap on the screen—an answer to the overwhelming expansion of medical knowledge and the burnout plaguing healthcare professionals.
Addressing Healthcare’s Growing Crisis
These innovations arrive as the industry faces a critical physician shortage and a relentless increase in the volume of medical research. OpenEvidence’s AI—trusted, fast, and always up-to-date—acts as a copilot for clinicians, empowering them to deliver the best care possible despite the pressures of understaffed hospitals and rapidly evolving medical science.
“Physicians are superheroes, and OpenEvidence is giving these superheroes new superpowers,” notes founder Daniel Nadler, underscoring the company’s commitment to making complex data actionable and keeping care at the cutting edge.
